Eiger BioPharmaceuticals (EIGR) Receives EMA Orphan Designation for Exendin 9-39 as NIPHS Treatment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/16/2024
- Dow up on UnitedHealth boost; higher bond yields, Mideast tensions cap gains
- UnitedHealth (UNH) beats earnings, revenue estimates in Q1; shares up
- BofA profit drops as provisions rise, but beats estimates on investment banking surge
- Morgan Stanley (MS) earnings beat lifts stock
- Johnson & Johnson (JNJ) posts mixed results, narrows full-year guidance
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- GE HealthCare (GEHC) Announces Resignation of Jan Makela, CEO of Imaging
- Biohaven Pharma (BHVN) presents update on degrader platform and summary of progress to date in Phase 1 single ascending dose study for BHV-1300
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
- Nike, Alpine Immune Sciences rise premarket; CarMax, Robinhood and Regeneron fall
Eiger Announces Orphan Designation of Exendin 9-39 for Treatment of Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) from European Medicines Agency (EMA)
October 17, 2016 8:00 AM EDTPALO ALTO, Calif., Oct. 17, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, announced today that the European Medicines Agency (EMA) has granted orphan designation to exendin 9-39 for the treatment of non-insulinoma pancreatogenous hypoglycemia syndrome (NIPHS). NIPHS describes a spectrum of acquired metabolic disorders characterized by inappropriately high insulin levels (hyperinsulinemia) and low blood glucose levels (hypoglycemia), which includes post-bariatric hypoglycemia (PBH).  Eiger is developing a novel subcutaneously administered form of exendin 9-39 for patients who experience dangerously low... More
